Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. - Wikidata - awgldk - TriplyDB

Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.

Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.

http://www.wikidata.org/entity/Q37383893

about

Molecular action of methotrexate in inflammatory diseases Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols Targeted approaches to induce immune tolerance for Pompe disease therapy Optimal management of steroid-dependent ulcerative colitis Quantitative gait analysis as a method to assess mechanical hyperalgesia modulated by disease-modifying antirheumatoid drugs in the adjuvant-induced arthritic rat Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis A case of clinical indolent natural killer cell lineage large granular lymphocytic leukemia in a patient with rheumatoid arthritis.Methotrexate Promotes Platelet Apoptosis via JNK-Mediated Mitochondrial Damage: Alleviation by N-Acetylcysteine and N-Acetylcysteine Amide.Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study.Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis.A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.Adenosine A2A receptor activation protects CD4+ T lymphocytes against activation-induced cell death.The effect of drugs and toxins on the process of apoptosis.Dietary transforming growth factor-beta 2 (TGF-β2) supplementation reduces methotrexate-induced intestinal mucosal injury in a rat.TNF inhibition as therapy for rheumatoid arthritis.Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis Smoking and rheumatoid arthritis.Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK.Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism.Azathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease.Adenosine in inflammatory joint diseases.Fas (CD95)-related apoptosis and rheumatoid arthritis.Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD.Esophageal sarcoidosis: a review of cases and an update.Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro.Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line.Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting.Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats.Treatment of early diffuse systemic sclerosis skin disease.IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide.Tuberculosis of spine: current views in diagnosis and management.Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.Review article: the role of non-biological drugs in refractory inflammatory bowel disease.Pediatric ulcerative colitis: a practical guide to management.Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics.Chronic Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: The Role of Systemic Immunomodulatory Therapy.

P2860

Q24534771-2E622889-85E8-4616-9FFC-32531B9D6BCC Q24674760-3988CE6C-2354-429A-8BAD-BB6525F9ECAB Q24793159-E1EC612D-2038-4CD0-B17B-9BFA946F8E7B Q26767363-9409358D-66F7-4F8C-8CF1-DEFB227856AE Q26773203-06E4141C-446B-41A9-A956-8CB18987CBA6 Q28221343-2CF01006-918E-4EA0-B675-81A8643B568C Q28375106-9BB65D5B-DD7B-4492-92D7-DCF83B9417E2 Q33349496-3C37AF5B-67F5-455E-B90F-0653DCB92E73 Q33423690-697846DC-FE2B-478F-8565-C90CE2D51CA3 Q33764331-F3FC5837-2A70-45E4-B301-438251055F82 Q33869850-4A5F5898-C8B8-400E-9CF8-911043726D61 Q33870942-1B6A5090-324D-4701-875C-851D2137D205 Q33983913-369F148A-0797-4A64-96C3-AC5E92670F6C Q34017174-9EE92D09-D8E9-4A01-86D9-7AB6E3A99833 Q34346312-E36648E3-8A11-4847-8733-67BF9B0A8850 Q34416431-092F305F-71F5-4FB0-9703-32B89BB84DE6 Q34706986-7709B1CC-3507-4E23-8B93-5E66BC0DD845 Q34828681-1D739BBB-89F2-4883-8922-0DBDE1AC5C1C Q34834289-4C49D5CA-0873-4037-939A-2919186F0BA5 Q35134668-B8B7B524-72BB-4161-8346-E86F782A3818 Q35138666-D45EB532-347D-44C5-B6C9-49F56516B961 Q35190872-47FCCBDD-8559-4B29-872C-619B7907B103 Q35967186-933F970A-4826-4C83-91C3-F8F2786092E9 Q36040498-4EA66AC2-AD01-4579-838B-8E11EAB19173 Q36174251-B685A106-48A1-48C6-9B45-013765AEAD0A Q36256257-4DEFADE7-40ED-4870-B495-1DDA6720E4DB Q36457546-683AE178-9D63-4398-95E8-9299AFCEAB84 Q36701625-73E32879-6B9C-4440-9999-22CA3654DEA2 Q36993938-A466ED64-70DA-496D-9EAA-DB2C5071D74D Q37193206-54F75689-C51F-42A3-B4A7-F3A82C7FB098 Q37362688-0B7E107D-D720-4E0C-8466-A29FCDFCE137 Q37400315-71772C1F-2EC8-41FF-8F3A-3EFA964ADA1A Q37467457-551BD510-1DFD-423F-896A-4E4DDA1677C1 Q37602033-828E2382-E6F6-49DB-81A8-D0664714A381 Q37611603-9A404529-8879-46EA-B2B4-42C8B63B3539 Q37728232-F5EC5894-4912-4651-AB82-D783D2FBD073 Q37817487-74F7EC8E-EB43-4AB8-86DF-AFD12F9A1520 Q38203832-41A6D31A-B5AC-4C57-9A29-F3F49B8B840A Q38609272-4529BAF3-8DDE-4494-8C64-9871934FF618 Q38766862-4A0E415F-1BF0-484E-B5B0-28C601C68C01

P2860

Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.

http://www.wikidata.org/entity/Q37383893

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 1998

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immunosuppressive properties o ...... activated peripheral T cells.

@en

Immunosuppressive properties o ...... activated peripheral T cells.

@nl

type

label

Immunosuppressive properties o ...... activated peripheral T cells.

@en

Immunosuppressive properties o ...... activated peripheral T cells.

@nl

prefLabel

Immunosuppressive properties o ...... activated peripheral T cells.

@en

Immunosuppressive properties o ...... activated peripheral T cells.

@nl

P1433

Q37383893-00CAFF3D-34B0-44DC-AFBD-199F103A6D13

P1476

Q37383893-656277B9-BF03-484E-81B1-1723C1EC25D8

P2093

Q37383893-08A08323-2339-4491-9DB8-857185E47EFA

Q37383893-92897B80-2ED0-456C-9468-1C94B82EA9B8

Q37383893-93196DE2-D895-4789-8337-7CD56749A8A4

Q37383893-9672B971-DBB0-43AF-B5E0-299E6C57E140

Q37383893-99449F58-1E00-45D1-A38B-A5FEAF4F8404

Q37383893-DDF21A71-5619-40B9-BAEB-BEDBC2AF6184

P2860

Q37383893-1F7EDD25-3A39-40C4-A23B-E1B5496A76B9

Q37383893-20AB6979-D5A7-4DF4-A662-020E72D89DCA

Q37383893-441C94AD-E1FC-4730-AA5E-F89A2965B977

Q37383893-56BCF052-D084-4518-82CC-3A158CB462E3

Q37383893-636FD51D-7BC6-42DE-A61D-9DE848086E08

Q37383893-65E4AF43-CBBF-413A-8644-67666B56A963

Q37383893-6F4009EB-3EC2-471E-9760-940C2CB8B41C

Q37383893-78236C5A-DEA0-41D0-BFDB-20176B4D6BC2

Q37383893-823D2443-AB6E-4BED-9264-14AB444EC14A

Q37383893-888A1F51-D4F5-4B2F-A212-13ED02572A12

P304

Q37383893-24B77009-A2A3-47A9-8600-39E1270971EE

P31

Q37383893-049AE42E-26EE-4678-870D-EC8D5F506B4B

P356

Q37383893-29C90AC9-8C41-4299-BAB7-7B6E44C20F8D

P407

Q37383893-EF470084-F9F9-4CA6-83F2-982082DD9BFC

P433

Q37383893-2E8D98CC-C1C0-4BEC-8BD9-B2DE52116B0F

P478

Q37383893-AEE75385-6C9F-4B98-88A5-F55F66E3C161

P577

Q37383893-68F67E26-8599-4C7D-A675-F550E2FEE6E6

P5875

Q37383893-4344D1A4-0EC8-4E05-BFB4-E04C8789DB93

P698

Q37383893-F23864FE-8F4C-4927-AD0A-C9F01DAC88D1

P921

Q37383893-00ECEC8A-B992-4871-827D-4AA9BF00B486

P932

Q37383893-14B174E4-A9B7-46B2-9863-8AE81D289A8B

P356

P1433

Journal of Clinical Investigation

P1476

Immunosuppressive properties o ...... activated peripheral T cells.

@en

P2093

Ferraro C

http://www.w3.org/2001/XMLSchema#string

Fournel S

http://www.w3.org/2001/XMLSchema#string

Genestier L

http://www.w3.org/2001/XMLSchema#string

Miossec P

http://www.w3.org/2001/XMLSchema#string

Paillot R

http://www.w3.org/2001/XMLSchema#string

Revillard JP

http://www.w3.org/2001/XMLSchema#string

P2860

Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.

Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.

The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis.

Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells.

Polyglutamation of methotrexate. Is methotrexate a prodrug?

Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo.

Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells

P304

322-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI2676

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

1998-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13620965

http://www.w3.org/2001/XMLSchema#string

P698

9664073

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

508890

http://www.w3.org/2001/XMLSchema#string